Novartis' bimagrumab gets breakthrough designation

Novartis AG (NYSE:NVS; SIX:NOVN) said FDA granted breakthrough therapy designation for bimagrumab ( BYM338) to treat sporadic inclusion body myositis (sIBM), for which it is in Phase II testing. Bimag...